Molecular and Cellular Biochemistry

, Volume 340, Issue 1–2, pp 55–62 | Cite as

CBP knockdown inhibits angiotensin II-induced vascular smooth muscle cells proliferation through downregulating NF-kB transcriptional activity

  • Jian Yang
  • Hong Jiang
  • Si-si Chen
  • Jing Chen
  • Sheng-kai Xu
  • Wan-qiang Li
  • Ji-chun Wang
Article

Abstract

CREB binding protein (CBP), a powerful transcriptional co-activator for various transcriptional factors, regulates cell behavior in many cell types. Angiotensin II (Ang II) contributes to vascular lesion by promoting vascular smooth muscle cells (VSMCs) proliferation and migration. Therefore, we examined whether CBP knockdown could suppress Ang II-induced VSMCs proliferation, and elucidated its underlying molecular mechanism. We constructed lentiviral vector expressing CBP-specific short hairpin RNAs (shRNAs) that efficiently silenced CBP. VSMCs proliferation was evaluated by bromodeoxyuridine (BrdU) incorporation assay. Protein and mRNA expression of CBP and relevant cytokines were examined by Western blot, ELISA, and real-time PCR, respectively. We also used luciferase reporter gene and electrophoretic mobility shift assay (EMSA) to detect Nuclear factor kappaB (NF-kB) transcriptional activity and DNA binding. Meanwhile, NF-kB p65 subunit nuclear translocation was confirmed by immunoblotting. Lentiviral-mediated CBP-shRNAs at different multiplicities of infection (MOI = 100, 150) both significantly suppressed Ang II-induced CBP expression. Knockdown of CBP markedly inhibited Ang II-stimulated VSMCs proliferation and cytokines (TNF-α and IL-6) production. However, this inhibitory effect was not enhanced at MOI of 150 compared with MOI of 100 (P > 0.05). CBP siRNA showed the potent inhibition on Ang II-induced NF-kB transcriptional activity. Similarly, no significant difference was found between CBP siRNA lentivirus treatment groups. Furthermore, CBP gene silencing had no effect on NF-kB nuclear translocation and DNA binding. These findings suggest that CBP knockdown inhibits Ang II-induced VSMCs proliferation and the mechanism is involved with downregulation of NF-kB transcriptional activity, not through reduction in NF-kB nuclear translocation or DNA binding. Maintaining proper CBP level may be a potential therapeutic target for Ang II-induced cardiovascular disorders.

Keywords

CBP Nuclear factor kappa-B Vascular smooth muscle cells RNA interference Gene therapy 

References

  1. 1.
    Takahashi T, Kawahara Y, Okuda M, Ueno H, Takeshita A, Yokoyama M (1997) Ang II stimulates mitogen-activated protein kinases and protein synthesis by a Ras-independent pathway in vascular smooth muscle cells. J Biol Chem 272:16018–16022CrossRefPubMedGoogle Scholar
  2. 2.
    Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA et al (2003) Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation 108:2270–2274CrossRefPubMedGoogle Scholar
  3. 3.
    Jia G, Cheng G, Agrawal DK (2006) Differential effects of insulin-like growth factor-1 and atheroma-associated cytokines on cell proliferation and apoptosis in plaque smooth muscle cells of symptomatic and asymptomatic patients with carotid stenosis. Immunol Cell Biol 84:422–429CrossRefPubMedGoogle Scholar
  4. 4.
    Nabata T, Morimoto S, Koh E, Shiraishi T, Ogihara T (1990) Interleukin-6 stimulates c-myc expression and proliferation of cultured vascular smooth muscle cells. Biochem Int 20:445–453PubMedGoogle Scholar
  5. 5.
    Schultz K, Murthy V, Tatro JB, Beasley D (2007) Endogenous interleukin-1 alpha promotes a proliferative and proinflammatory phenotype in human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 292:H2927–H2934CrossRefPubMedGoogle Scholar
  6. 6.
    Cheng G, Kim MJ, Jia G, Agrawal DK (2007) Involvement of chloride channels in IGF-I-induced proliferation of porcine arterial smooth muscle cells. Cardiovasc Res 73:198–207CrossRefPubMedGoogle Scholar
  7. 7.
    Brasier AR, Jamaluddin M, Han Y, Patterson C, Runge MS (2000) Angiotensin II induces gene transcription through cell-type-dependent effects on the nuclear factor-kappaB (NF-kappaB) transcription factor. Mol Cell Biochem 212:155–169CrossRefPubMedGoogle Scholar
  8. 8.
    Chen Y, Zheng J, Zhang Y, Wang J, Liu Q, Huang Z et al (2009) N-4-tert-butyl benzyl haloperidol chloride suppresses Ca2+-dependent Egr-1 expression and subsequently inhibits vascular smooth muscle cell proliferation induced by angiotensin II. Cell Physiol Biochem 23:295–304CrossRefPubMedGoogle Scholar
  9. 9.
    Bellas RE, Lee JS, Sonenshein GE (1995) Expression of a constitutive NF-kappa B-like activity is essential for proliferation of cultured bovine vascular smooth muscle cells. J Clin Invest 96:2521–2527CrossRefPubMedGoogle Scholar
  10. 10.
    Barnes PJ, Karin M (1997) Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066–1071CrossRefPubMedGoogle Scholar
  11. 11.
    O’Suilleabhain CB, Kim S, Rodrick MR, Mannick JA, Lederer JA (2001) Injury induces alterations in T-cell NFkappaB and AP-1 activation. Shock 15:432–437CrossRefPubMedGoogle Scholar
  12. 12.
    Hernández-Presa M, Bustos C, Ortego M, Tuñon J, Renedo G, Ruiz-Ortega M et al (1997) Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 95:1532–1541PubMedGoogle Scholar
  13. 13.
    Yamamoto K, Shioi T, Uchiyama K, Miyamoto T, Sasayama S, Matsumori A (2003) Attenuation of virus-induced myocardial injury by inhibition of the angiotensin II type 1 receptor signal and decreased nuclear factor-kappa B activation in knockout mice. J Am Coll Cardiol 42:2000–2006CrossRefPubMedGoogle Scholar
  14. 14.
    Zahradka P, Werner JP, Buhay S, Litchie B, Helwer G, Thomas S (2002) NF-kappaB activation is essential for angiotensin II-dependent proliferation and migration of vascular smooth muscle cells. J Mol Cell Cardiol 34:1609–1621CrossRefPubMedGoogle Scholar
  15. 15.
    Fujita N, Furukawa Y, Du J, Itabashi N, Fujisawa G, Okada K et al (2002) Hyperglycemia enhances VSMC proliferation with NF-kappaB activation by angiotensin II and E2F-1 augmentation by growth factors. Mol Cell Endocrinol 192:75–84CrossRefPubMedGoogle Scholar
  16. 16.
    Arany Z, Sellers WR, Livingston DM, Eckner R (1994) E1A-associated p300 and CREB-associated CBP belong to a conserved family of coactivators. Cell 77:799–800CrossRefPubMedGoogle Scholar
  17. 17.
    Goodman RH, Smolik S (2000) CBP/p300 in cell growth, transformation, and development. Genes Dev 14:1553–1577PubMedGoogle Scholar
  18. 18.
    Chrivia JC, Kwok RP, Lamb N, Hagiwara M, Montminy MR, Goodman RH (1993) Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 365:855–859CrossRefPubMedGoogle Scholar
  19. 19.
    Shiama N (1997) The p300/CBP family: integrating signals with transcription factors and chromatin. Trends Cell Biol 7:230–236CrossRefPubMedGoogle Scholar
  20. 20.
    Du Z, Wei L, Murti A, Pfeffer SR, Fan M, Yang CH et al (2007) Non-conventional signal transduction by type 1 interferons: the NF-kappaB pathway. J Cell Biochem 102:1087–1094CrossRefPubMedGoogle Scholar
  21. 21.
    Selzman CH, Shames BD, Reznikov LL, Miller SA, Meng X, Barton HA et al (1999) Liposomal delivery of purified inhibitory-kappaBalpha inhibits tumor necrosis factor-alpha-induced human vascular smooth muscle proliferation. Circ Res 84:867–875PubMedGoogle Scholar
  22. 22.
    Matt T (2002) Transcriptional control of the inflammatory response: a role for the CREB-binding protein (CBP). Acta Med Austriaca 29:77–79CrossRefPubMedGoogle Scholar
  23. 23.
    Chen J, Jiang H, Xu L, Zhu LH, Wang L, Wen HZ et al (2008) Dysregulation of CREB binding protein triggers thrombin-induced proliferation of vascular smooth muscle cells. Mol Cell Biochem 315:123–130CrossRefPubMedGoogle Scholar
  24. 24.
    Tokunou T, Shibata R, Kai H, Ichiki T, Morisaki T, Fukuyama K et al (2003) Apoptosis induced by inhibition of cyclic AMP response element-binding protein in vascular smooth muscle cells. Circulation 108:1246–1252CrossRefPubMedGoogle Scholar
  25. 25.
    Ma Y, Zhang L, Peng T, Cheng J, Taneja S, Zhang J et al (2006) Angiotensin II stimulates transcription of insulin-like growth factor I receptor in vascular smooth muscle cells: role of nuclear factor-kappaB. Endocrinology 147:1256–1263CrossRefPubMedGoogle Scholar
  26. 26.
    Han Y, Runge MS, Brasier AR (1999) Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors. Circ Res 84:695–703PubMedGoogle Scholar
  27. 27.
    Wolf G, Wenzel UO (2004) Angiotensin II and cell cycle regulation. Hypertension 43:693–698CrossRefPubMedGoogle Scholar
  28. 28.
    Ghosh S, Karin M (2002) Missing pieces in the NF-kappaB puzzle. Cell 109(Suppl):S81–S96CrossRefPubMedGoogle Scholar
  29. 29.
    Rovin BH, Dickerson JA, Tan LC, Fassler J (1997) Modulation of IL-1-induced chemokine expression in human mesangial cells through alterations in redox status. Cytokine 9:178–186CrossRefPubMedGoogle Scholar
  30. 30.
    Shah RD, Gonzales F, Golez E, Augustin D, Caudillo S, Abbott A et al (2005) The antidiabetic agent rosiglitazone upregulates SERCA2 and enhances TNF-alpha- and LPS-induced NF-kappaB-dependent transcription and TNF-alpha-induced IL-6 secretion in ventricular myocytes. Cell Physiol Biochem 15:41–50CrossRefPubMedGoogle Scholar
  31. 31.
    Takahashi N, Tetsuka T, Uranishi H, Okamoto T (2002) Inhibition of the NF-kappaB transcriptional activity by protein kinase A. Eur J Biochem 269:4559–4565CrossRefPubMedGoogle Scholar
  32. 32.
    Schmitz ML, Mattioli I, Buss H, Kracht M (2004) NF-kappaB: a multifaceted transcription factor regulated at several levels. Chembiochem 5:1348–1358CrossRefPubMedGoogle Scholar
  33. 33.
    Sheppard KA, Rose DW, Haque ZK, Kurokawa R, McInerney E, Westin S et al (1999) Transcriptional activation by NF-kappaB requires multiple coactivators. Mol Cell Biol 19:6367–6378PubMedGoogle Scholar
  34. 34.
    Chan HM, La Thangue NB (2001) p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci 114:2363–2373PubMedGoogle Scholar
  35. 35.
    Glozak MA, Sengupta N, Zhang X, Seto E (2005) Acetylation and deacetylation of non-histone proteins. Gene 363:15–23CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Jian Yang
    • 1
  • Hong Jiang
    • 1
  • Si-si Chen
    • 1
  • Jing Chen
    • 1
  • Sheng-kai Xu
    • 1
  • Wan-qiang Li
    • 2
  • Ji-chun Wang
    • 1
  1. 1.Department of CardiologyRenmin Hospital of Wuhan UniversityWuhanChina
  2. 2.Department of UrologyRenmin Hospital of Wuhan UniversityWuhanChina

Personalised recommendations